Sublingual Buprenorphine as an Analgesic in Chronic Pain: A Systematic Review

被引:106
作者
Cote, Joyce [1 ]
Montgomery, Lori [1 ,2 ,3 ]
机构
[1] Alberta Hlth Serv, Chron Pain Ctr, Calgary, AB T2T 5C7, Canada
[2] Univ Calgary, Dept Family Med, Calgary, AB, Canada
[3] Univ Calgary, Dept Anesthesia, Calgary, AB, Canada
关键词
Buprenorphine; Chronic Pain; Systematic Reviews; SUB-LINGUAL BUPRENORPHINE; TRANSDERMAL BUPRENORPHINE; OPIOID THERAPY; DOUBLE-BLIND; CANCER PAIN; OSTEOARTHRITIS; COMBINATION; CONVERSION; EFFICACY; SAFETY;
D O I
10.1111/pme.12386
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Objective. There is growing interest in the use of sublingual buprenorphine for the treatment of chronic pain due to the unique pharmacology of buprenorphine, widespread use of the transdermal buprenorphine patch for chronic pain, and recent availability of sublingual buprenorphine tablets for the treatment of opioid dependence. The aim of this systematic review was to evaluate the evidence from clinical trials that have assessed the effectiveness of sublingual buprenorphine for chronic pain analgesia. Methods. Electronic searches of MEDLINE, Embase, CINAHL, Web of Science, and the Cochrane Database of Systematic Reviews were used to identify clinical trials of sublingual buprenorphine for the treatment of chronic pain. Results. Ten trials involving 1,190 patients were included in the review. Due to heterogeneity of studies, pooling of the results and meta-analysis were not possible. All studies reported that sublingual buprenorphine demonstrated some effectiveness as a chronic pain analgesic. The majority of studies were observational and of low quality. Conclusions. Preliminary trials suggest a plausible role; however, due to a paucity of high-quality trials, the current evidence is insufficient to determine the effectiveness of sublingual buprenorphine for the treatment of chronic pain. Rigorous further trials are warranted.
引用
收藏
页码:1171 / 1178
页数:8
相关论文
共 43 条
[1]  
ADRIAENSEN H, 1985, Acta Anaesthesiologica Belgica, V36, P33
[2]  
[Anonymous], BUTRANS PROD MON
[3]  
[Anonymous], PUBL ASS REP TOPH 20
[4]  
[Anonymous], FDA APPR DRUG PROD
[5]  
[Anonymous], 2012, BUPRENORPHINE NALOXO
[6]  
[Anonymous], 2010, CAN GUID SAF EFF US
[7]  
[Anonymous], AM J HEMATOL
[8]  
[Anonymous], SUB PROD MON
[9]  
[Anonymous], TRANST 35 52 5 70 MI
[10]  
[Anonymous], BUTRANS PROD LAB